title: Engineering antibody therapeutics.
abstract: The successful introduction of antibody-based protein therapeutics into the arsenal of treatments for patients has within a few decades fostered intense innovation in the production and engineering of antibodies. Reviewed here are the methods currently used to produce antibodies along with how our knowledge of the structural and functional characterization of immunoglobulins has resulted in the engineering of antibodies to produce protein therapeutics with unique properties, both biological and biophysical, that are leading to novel therapeutic approaches. Antibody engineering includes the introduction of the antibody combining site (variable regions) into a host of architectures including bi and multi-specific formats that further impact the therapeutic properties leading to further advantages and successes in patient treatment.
authors.affiliation: Janssen Research & Development LLC, 1400 McKean Road, Spring House, PA 19477, USA. Electronic address: mchiu@its.jnj.com.
authors.forename: Mark L
authors.initials: ML
authors.lastname: Chiu
authors.affiliation: Janssen Research & Development LLC, 1400 McKean Road, Spring House, PA 19477, USA. Electronic address: ggillila@its.jnj.com.
authors.forename: Gary L
authors.initials: GL
authors.lastname: Gilliland
mesh_terms: D000818:Animals; D000906:Antibodies / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D015202:Protein Engineering / Q000379:methods*; D014018:Tissue Distribution
chemical_list: D000906:Antibodies